Kestra Advisory Services, LLC Aldeyra Therapeutics, Inc. Transaction History

Kestra Advisory Services, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 01, 2022	SELL	$3.8 - $7.74 $3,040 - $6,192	-800 Reduced 4.46%	17,138 $92 Million
Q1 2022 Apr 26, 2022	BUY	$3.25 - $5.17 $3,669 - $5,836	1,129 Added 6.72%	17,938 $79,000
Q4 2021 Jan 20, 2022	BUY	$3.5 - $9.63 $14,742 - $40,561	4,212 Added 33.44%	16,809 $67,000
Q2 2021 Jul 28, 2021	BUY	$10.44 - $14.85 $2,401 - $3,415	230 Added 1.86%	12,597 $142,000
Q1 2021 May 10, 2021	SELL	$6.53 - $14.42 $48,322 - $106,708	-7,400 Reduced 37.44%	12,367 $146,000
Q4 2020 Jan 20, 2021	BUY	$6.31 - $8.13 $124,729 - $160,705	19,767 New	19,767 $135 Million

117

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $283M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Kestra Advisory Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Kestra Advisory Services, LLC with notifications on news.